Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

  • Retinal disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT).

Methods

Intravitreal bevacizumab (1.25 mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRNV due to IJT in this nonrandomized, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) findings were examined before and after treatment. The patients were followed up for 3–6 months.

Results

Pre-injection BCVA measured 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 months, post-injection BCVA measured 20/200 to 20/50 (mean 20/100). At last visit BCVA improved two or more lines in five eyes (83%) and remained the same in one eye (17%). The mean central foveal thickness improved from 263 μm (range, 165 to 393 μm) to 201 μm (range, 126 to 351 μm), representing an average reduction of 62 μm. Only one eye received more than one (2) bevacizumab injections. No significant complications were observed.

Conclusions

In this small series, intravitreal bevacizumab appears to be a safe and effective treatment for SRNV secondary to type 2A IJT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Reference

  1. Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveal retinal telangiectasis. Arch Ophthalmol 100:769–780

    PubMed  CAS  Google Scholar 

  2. Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546

    PubMed  CAS  Google Scholar 

  3. Gass JDM (1997) Retinal capillary diseases. In: Stereoscopic atlas of macular diseases, 4th edn. Mosby, St Louis, pp 506–510

    Google Scholar 

  4. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819

    Article  PubMed  CAS  Google Scholar 

  5. Engelbrecht NE, Aaberg TM, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120:320–324

    PubMed  Google Scholar 

  6. Berger AS, McCuen BW II, Brown GC, Brownlow RL Jr (1997) Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 17:94–98

    Article  PubMed  CAS  Google Scholar 

  7. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  8. Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9

    Article  PubMed  CAS  Google Scholar 

  9. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91(2):157–160

    Article  PubMed  Google Scholar 

  10. Sakaguchi H, Ikuno Y, Gomi F et al (2007) Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91(2):161–165

    Article  Google Scholar 

  11. Potter MJ, Szabo SM, Chan EY, Morris AH (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133:149–151

    Article  PubMed  Google Scholar 

  12. Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 53:61–63

    Article  PubMed  Google Scholar 

  13. Smithen LM, Spaide RF (1997) Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Retina 17:94–98

    Google Scholar 

  14. Jorge R, Costa RA, Calucci D, Scott IU (2006) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol, Nov 29 (Epub ahead of print)

Download references

Author information

Authors and Affiliations

  1. Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110029, India

    Subrata Mandal, Pradeep Venkatesh, Zahir Abbas, Rajpal Vohra & Satpal Garg

Authors
  1. Subrata Mandal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pradeep Venkatesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahir Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajpal Vohra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satpal Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subrata Mandal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mandal, S., Venkatesh, P., Abbas, Z. et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245, 1825–1829 (2007). https://doi.org/10.1007/s00417-007-0567-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-007-0567-8

Keywords

Search

Navigation